Search filters
Filters
Clear All

Phase

  • 3
  • 3
  • 7
  • 3
  • 17
  • 8
  • 17

Found 17 Cardiomyopathy trials

A listing of Cardiomyopathy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Studying the Safety and Effectiveness of an Investigation Drug Danicamtiv in Patients with Dilated Cardiomyopathy

18 years - 80 years
All genders
Interventional
The purpose of Part A of this study is to evaluate the safety, tolerability, and cardiac pharmacodynamics (the effect of the study drug on your heart) of the study drug, danicamtiv, when administered by mouth twice a day for approximately one to two weeks. Part A which may last between …
Learn More
Studying symptomatic Transthyretin Amyloid Cardiomyopathy for those who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)

Studying symptomatic Transthyretin Amyloid Cardiomyopathy for those who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)

18 years - 99 years
All genders
Phase 3
This open-label study is designed to evaluate the long-term safety and tolerability of acoramidis in participants with ATTR-CM, administered on a background of stable heart failure therapy. This study follows the randomized, double-blind, placebo-controlled Study AG10-301 which was designed to examine safety and efficacy in this same population.
Learn More

Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy

19 years - 99 years
All genders
Phase 3
Interventional
The purpose of this study is to compare the effects of the study drug versus a placebo on reducing the number of septal reduction therapy procedures performed in patients with symptomatic oHCM.
Learn More
A Randomized Double-blind Placebo-controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

A Randomized Double-blind Placebo-controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

99 years or below
All genders
Phase 3
This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter, international, parallel-group study to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo (1:1) in participants with symptomatic oHCM. Approximately 220 participants will be enrolled. This includes ~80 participants (~40 per treatment group) who consent to participate in a …
Learn More

Study to Evaluate Safety and Efficacy of Ck3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

18 years - 99 years
All genders
Phase 3
The purpose of this study is to compare the effects of CK-3773274, and placebo, on the exercise and health status of patients with oHCM. The safety and tolerability of CK-3773274 will also be studied.
Learn More

A Long-Term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)

99 years or below
All genders
This is a multicenter study to evaluate the long-term safety and tolerability of mavacamten in participants with nHCM who completed MAVERICK-HCM through Week 24 and enroll into this study within 3 months. All participants will receive active study drug as described below, but their status (active or placebo) in the …
Learn More
Multicenter randomized double-blind parallel-group add-on superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera )

Multicenter randomized double-blind parallel-group add-on superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera )

99 years or below
All genders
Phase 3
This is a study to find out whether patients with active forms of Relapsing Multiple Sclerosis (RMS) who are treated with dimethyl fumarate (Tecfidera®) can be treated better by the addition of ponesimod (study drug). The purpose is also to evaluate the effect on disability and the safety of these …
Learn More
11 - 17 of 17